Skip to content
Open access

ZEB1 directly activates IL-6 to promote triple-negative breast cancer stemness in an epigenetically constrained context

Sep 2026 · Frontiers in Oncology · Vol 16 · 0 citations · 32 references
Medicine

TL;DR

The findings establish the ZEB1–IL-6 axis as an important regulator of triple-negative breast cancer (TNBC) stemness and indicate that ZEB1-dependent IL-6 activation is influenced by the local epigenetic context, which supports further investigation of the ZEB1-high TNBC.

Abstract

ZEB1 is a key driver of breast cancer pathogenesis and therapy resistance, largely through its ability to promote cancer stem cells (CSCs). Although tumor-secreted cytokines such as IL-6 are known to support tumor progression, how their expression is regulated by upstream transcriptional factors such as ZEB1 remains incompletely understood. Here, we identify IL-6 as a direct transcriptional target of ZEB1 and reveal an epigenetic dimension associated with this regulation. Mechanistically, ZEB1 binds to specific E2-box elements within the IL-6 promoter and activates its transcription. The IL-6 promoter exhibits local DNA methylation, and ZEB1-dependent IL-6 expression was further enhanced by DNA methyltransferase and histone deacetylase inhibitors, suggesting that the local epigenetic context constrains IL-6 transcription. ZEB1 overexpression was also accompanied by enrichment of the active histone marks H3K27ac and H3K4me3 at the IL-6 promoter, consistent with a more transcriptionally permissive local chromatin state. Functionally, the ZEB1-induced IL-6 expression enhanced CSC-associated properties in vitro and tumor-initiating capacity in vivo. Conversely, IL-6 knockdown attenuated ZEB1-induced CSC-associated phenotypes, whereas pharmacological IL-6 neutralization reduced xenograft burden and CSC-associated populations in vivo. Collectively, our findings establish the ZEB1–IL-6 axis as an important regulator of triple-negative breast cancer (TNBC) stemness and indicate that ZEB1-dependent IL-6 activation is influenced by the local epigenetic context. These findings support further investigation of the ZEB1–IL-6 axis as a potential therapeutic target in ZEB1-high TNBC.

Read PDF

Similar papers

Open access Sep 2026

The DCBLD2 super-enhancer drives colorectal cancer progression through FOSL2/JUND-mediated activation of the CD146/AKT/TNFRSF6B pathway

This study uncovers a previously undescribed DCBLD2-centered regulatory cascade that promotes colorectal cancer initiation and progression and represents promising prognostic biomarkers and actionable therapeutic targets for colorectal cancer.

Tong Wu, Lan Shao, Xin Hu et al. · 0 citations
Open access Oct 2026

HIF-1–mediated PPME1 expression promotes breast cancer progression via AKT activation and β-catenin recruitment

Hypoxia-inducible factor 1 (HIF-1) orchestrates the transcriptional regulation of thousands of genes involved in breast cancer (BC) progression. Here, we identified protein phosphatase 2A (PP2A) methylesterase 1 (PPME1) as a critical HIF-1 target gene that drives oncogenic signaling under hypoxic conditions. In BC cell...

Yajing Lyu, Varen Talwar, Yong-Kang Yang et al. · 0 citations
Open access Sep 2026

ACTB promotes ESCC progression by regulating the AKT–mTOR signaling pathway through an m6A-dependent mechanism

Esophageal squamous cell carcinoma (ESCC) is a highly aggressive malignancy with poor prognosis, and the upstream regulatory mechanisms driving oncogenic signaling remain insufficiently defined. In this study, we identify a previously unrecognized nuclear function of the cytoskeletal protein ACTB in promoting ESCC prog...

Yun-Shan Jiang, Dan Zhao, D. Liao et al. · 0 citations
Open access Oct 2026

Acetylation-driven non-canonical transcriptional repressor ITSN1-S targets RASGRF1-GPX4 axis to induce breast cancer ferroptosis and anti-tumor immune remodeling

Breast cancer remains the most prevalent malignancy among women worldwide, yet robust molecular biomarkers are still lacking to advance precision oncology. Integrative analyses of our single-cell RNA sequencing (scRNA-seq) and mRNA microarray datasets identified endocytic protein, the short isoform of intersectin 1...

Hui-Kun Zhang, Si-Qing Sun, Ya-Wen Zhao et al. · 0 citations
Open access Sep 2026

Histone demethylase KDM4A promotes endometrial cancer progression through an ERRγ-associated cell-cycle regulatory axis

Endometrial cancer (EC) is driven by complex genetic and epigenetic alterations, but the specific chromatin-dependent mechanisms that sustain malignant proliferation remain incompletely understood. In this study, we found that lysine demethylase 4A (KDM4A) was upregulated in EC and promoted cell proliferation, migratio...

Jun-Feng Chen, Xiao-Li Wen, Dong-Hai Zhang et al. · 0 citations
Open access Sep 2026

ZBTB10 inhibits ccRCC progression by epigenetically silencing GPX4 through a self-regulatory ZBTB10/DNMT1/FBXW4 loop

ZBTB10 is identified as a suppressor of ccRCC progression that transcriptionally represses GPX4, a central inhibitor of ferroptosis and an epigenetic mechanism linking ZBTB10 to ferroptosis in ccRCC is revealed and targeting the ZBTB10/DNMT1/FBXW4/GPX4 axis may provide a therapeutic strategy for limiting ccRCC progress...

Wei Song, Hou-Liang Zhang, Yi-Di Wang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.